

Statement of Cooperation

Context

Queensland has a unique opportunity to leverage government, university and industry investment to transform itself into a globally recognised biomedical destination.

Over the last two decades, the Queensland Government has made significant investments to develop a thriving biomedical research community within the state. The Government is committed to continuing that investment and building partnerships that will transform the sector into an end-to-end, world-leading biomedical ecosystem.

This commitment is one which supports the development, attraction, and retention of talent, brings in new industry players, investment and job opportunities, and builds the pipeline of activities that drives the development of new vaccines, drugs and delivery of health care solutions – for Queenslanders and the global community.

The vision in the *Queensland Biomedical 10-Year Roadmap and Action Plan* to be a globally competitive Asia-Pacific biomedical hub by 2027, demonstrates the Queensland Government's ongoing commitment to facilitate new collaborations and opportunities, helps pave new career pathways for researchers, clinicians and industry, enhances our sovereign capability, and supports scale up of biomanufacturing facilities.

Our world-class research base with key innovation precincts and an educated, highly-skilled workforce, with access to high growth Asia-Pacific markets makes Queensland's biomedical sector strong.

Government, major industry and the research sector are all strongly committed to developing our thriving biomedical ecosystem.

Purpose

This Statement of Cooperation (SoC) sets out the strategic intention of the foundational partnership between the Queensland Government, Sanofi, The University of Queensland and Griffith University, with a view to welcoming compatible future partners, to collectively catalyse the growth of Queensland's biomedical ecosystem to maximise the potential economic uplift in the longer-term.

The partners agree to develop a shared strategy with both short and long-term goals, to foster collaboration and align interests.

An immediate opportunity is Sanofi's intent to establish a global Translational Science Hub (TSH) in Queensland with the support of the Queensland Government, Griffith University, and The University of Queensland.

Queensland has the opportunity to be at the forefront of innovative vaccine research and development, and in partnership with Sanofi, unlock the value of local research.

Whilst the TSH will start with a five-year commitment on specific vaccine opportunities, the goal of the TSH in the longer term is to expand activities to encompass a number of vaccines and other therapeutics.

The stakeholders will work together to secure the ecosystem benefits of the TSH, starting with a five-year commitment, but looking well beyond that timeframe, supported by a comprehensive strategy that will enable further beneficial partnerships to be formed. Subject to entering into binding legal agreements, the parties, in parallel to the establishment of the TSH, will work to:

- Establish formal mechanisms for a governance framework with agreed oversight of the operations to deliver research projects and fee for service activities as part of the TSH.
- Develop a financial structure to deliver return on investment for each stakeholder.
- Consider the range of facilities and clinical trial research agreements between Sanofi and each partner (as required). It is proposed that specific clinical trials may be managed directly between a university partner, Queensland Government entities and Sanofi as appropriate.
- Consider the requirements for establishing a series of research projects with work packages for preclinical and development work performed by university investigators, managed directly between the University partners and Sanofi.

The intent of the proposed governance arrangement is to ensure there is knowledge sharing among parties (where applicable) and also to maximise intent for collaborations and further partnerships, including ways to fulfill the long-term, strategic objectives which include:

- Embedding Sanofi as part of the Queensland ecosystem.
- Developing the ecosystem's long-term joint strategy to see more opportunities for complementary business growth and attraction, along with capability development.
- Building further capacity at Queensland universities and a strong and attractive pathway for more students to engage in research in the related areas.
- Providing an international standard of integrated industry work and learning experiences for Queensland students.
- Attracting and retaining world-leading experts in the biomedical sciences, further enhancing creativity and positive health outcomes in the local ecosystem.



COMMERCIAL IN CONFIDENCE

- Building Queensland's sovereign capability and relevant expertise in the biomedical sector.

The initial establishment of the TSH is to serve as a nucleus to bring together the local academic and industry network with the extensive research and translational and clinical development capacities across global Sanofi functions.

The TSH will be part of the Sanofi Global R&D organization, with close interaction and synergy with the well-established Queensland R&D ecosystem.

This Statement of Cooperation demonstrates a fruitful and long-term commitment by the parties which will continue to grow and evolve as opportunities arise from this major partnership.

Foundational Partners

This Statement of Cooperation demonstrates the intention of partnership between industry, the Queensland Government and Queensland universities. The four foundational partners are listed below:

- **Griffith University** is a public research university located in Queensland, committing to advancing scientific research in Australia. The University could bring significant skills and assets to the TSH objectives. Its Institute for Glycomics, the Menzies Health Institute of Queensland (MHIQ), and the Griffith Institute for Drug Discovery (GRIDD) all have teams with world-leading mRNA and related technologies, and state of the art facilities. In addition, their Clinical Trials Unit (CTU) utilises a variety of clinical trial participant recruitment pathways. In a traditional sense the CTU recruits through direct referrals from private and public clinicians who are also investigators on the trials.
- **The University of Queensland** is a public research university located in Queensland, committing to advancing scientific research in Australia. The University could bring significant skills and assets to the TSH objectives. The Translational Research Institute (TRI) is a leading Australian innovative medical research, development and translation facility. As an institute focused on research translation, TRI is charged with partnering scientific development with the commercial sector to ensure innovations move rapidly to improve patient outcomes and commercial return. To this end, TRI is at the interface of science, medicine and industry. TRI combines the research intellect and capability of Queensland Health, The University of Queensland, Queensland University of Technology and the Mater Health Service through Mater Research. Sanofi will be the anchor tenant at the Translational Manufacturing facility at TRI (TM@TRI).
- **Sanofi** is one of the world's largest innovative global healthcare companies that provides potentially life-changing treatment options and life-saving vaccine protection to

millions of people. Sanofi is located in 100 countries, with 70 manufacturing sites and 20 R&D sites around the world exploring new medicines and vaccines. This work is done with sustainability and social responsibility at the centre of their ambitions.

In Australia, Sanofi is one of the top 5 medicines and vaccines companies, with 50 medicines on the Pharmaceutical Benefits Scheme, 5 Rare Disease therapies on the Life Saving Drugs Program, and 17 vaccines available, with 7 on the National Immunisation Program.

Sanofi's global mRNA Center of Excellence is currently working to accelerate the development of next-generation vaccines by integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls teams, across Cambridge in the US and Lyon in France.

- The **Queensland Government** through Department of State Development, Infrastructure, Local Government and Planning, the Department of Environment and Science, and Queensland Health will be a key catalyst for the TSH by providing a significant proportion of the funding for its establishment and ensuring the various stakeholders in the Queensland biomedical ecosystem are connected and working towards the same objective. Queensland Health is one of the largest single providers of hospital care in Australia, with advanced capabilities in electronic health records and digital health platforms. These data assets inform improved models of clinical trial feasibility and recruitment, and are actively being assessed to support clinical trials and other collaborations that enhance real world evidence research for burden of disease and vaccine effectiveness.


Implementation

All parties are committed to positive outcomes from this partnership, however this Statement does not create any binding contractual arrangements or create any expectations of entering into any contractual arrangements based on any representations made by Sanofi, the Queensland Government, Griffith University or The University of Queensland.

Any legally binding commitment of funding to the TSH by the Queensland Government, Griffith University and The University of Queensland is subject to the execution of formal binding agreements between the parties.

The Foundational Parties are moving quickly to formalise the objectives in this Statement of Cooperation and will meet regularly. This collaboration, to be formalised under a governance structure, will be pivotal to realise the vision.

Parties will review this statement as required.



COMMERCIAL IN CONFIDENCE

Statement of Cooperation



Dr Jean-Francois Toussaint
Global Head Research &
Development Vaccines, Sanofi

sanofi




Professor Carolyn Evans
Vice Chancellor and President,
Griffith University


Griffith
UNIVERSITY
Queensland, Australia




Professor Deborah Terry
Vice-Chancellor and President,
The University of Queensland


THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA



The Honourable
Anastacia Palaszczuk MP
Premier and Minister
for the Olympics



The Honourable
Dr Steven Miles MP
Deputy Premier and Minister
for State Development,
Infrastructure, Local Government
and Planning and Minister
Assisting the Premier on
Olympics Infrastructure



The Honourable
Meaghan Scanlon MP
Minister for the Environment
and the Great Barrier Reef and
Minister for Science and
Youth Affairs



Queensland
Government